b
r
c
ebola
ebov
zika
virus
zikv
respons
recent
global
health
threat
prevent
vaccin
antivir
drug
two
reemerg
pathogen
avail
evalu
whether
molecular
tweezer
may
inhibit
ebov
zikv
infect
small
molecul
previous
shown
inactiv
herp
virus
select
interact
lipidraftrich
region
viral
envelop
result
membran
disrupt
loss
infect
found
inde
block
infect
ebov
zikv
dosedepend
manner
tweezer
inhibit
infect
epidem
zikv
strain
cell
deriv
anogenit
tract
central
nervou
system
remain
antivir
activ
presenc
semen
saliva
urin
cerebrospin
fluid
find
show
broadspectrum
inhibitor
envelop
virus
prospect
prevent
microbicid
antivir
agent
zika
viru
zikv
first
isol
febril
rhesu
macaqu
zika
forest
uganda
dick
et
al
sinc
sporad
zikv
infect
occur
africa
asia
haddow
et
al
hay
zikv
infect
usual
associ
mild
symptom
thu
viru
consid
threaten
pathogen
howev
sinc
recent
outbreak
evid
zikv
caus
drastic
birth
defect
promin
microcephali
mlakar
et
al
rasmussen
et
al
associ
neurolog
disord
syndrom
caolormeau
et
al
krauer
et
al
sinc
countri
territori
report
ongo
zikv
transmiss
http
www
whointemergencieszikavirusen
brazil
alon
million
person
infect
shuaib
et
al
prompt
declar
zikv
public
health
emerg
intern
concern
current
specif
treatment
vaccin
zikv
make
develop
effect
prevent
measur
urgent
public
health
need
barrow
et
al
et
al
zikv
transmit
mainli
via
mosquito
bite
case
sexual
transmiss
also
http
report
dortenzio
et
al
moreira
et
al
petersen
et
al
like
member
flavivirida
famili
eg
dengu
viru
zika
virion
surround
hostmembranederiv
lipid
bilay
contain
envelop
glycoprotein
respons
cell
entri
sirohi
et
al
ebola
viru
ebov
discov
near
ebola
river
former
zair
sinc
outbreak
sporad
occur
africa
sever
reach
epidem
proport
death
toll
peopl
center
diseas
control
prevent
cdc
ebov
belong
famili
filovirida
form
envelop
filament
infecti
particl
caus
hemorrhag
fever
rare
deadli
diseas
high
fatal
rate
addit
global
health
concern
viru
also
consid
potenti
biolog
threat
agent
ebov
like
transmit
infect
bat
human
may
spread
person
contact
contamin
object
sexual
intercours
mate
et
al
pandey
et
al
noteworthi
even
recoveri
ebov
found
bodi
fluid
includ
semen
sever
month
deen
et
al
licens
vaccin
medicin
avail
prevent
manag
futur
ebov
outbreak
sharma
ketki
jangid
molecular
tweezer
novel
drug
candid
treatment
amyloidosi
relat
condit
lead
compound
use
mani
vitro
vivo
studi
date
schrader
et
al
bind
lysin
residu
polypeptid
disrupt
noncoval
molecular
interact
import
abnorm
selfassembl
lead
format
toxic
oligom
amyloid
aggreg
schrader
et
al
sinha
et
al
fact
prevent
assembl
promot
disaggreg
amyloid
fibril
associ
neurodegen
diseas
ferreira
et
al
prabhudesai
et
al
richter
et
al
therapeut
effect
demonstr
anim
model
parkinson
diseas
lulla
prabhudesai
et
al
richter
et
al
alzheim
diseas
malik
et
al
famili
amyloidot
polyneuropathi
fap
ferreira
et
al
desminrel
cardiomyopathi
found
safe
mice
dose
higher
show
therapeut
effect
recent
establish
also
disrupt
format
amyloid
fibril
semen
lump
et
al
enhanc
infect
et
al
usmani
et
al
surprisingli
also
inhibit
infect
direct
virusinactiv
mechan
tweezer
preferenti
bound
raftrich
region
viral
membran
result
disrupt
lipid
bilay
loss
infect
line
membran
target
activ
inact
nonenvelop
virus
human
adenoviru
destroy
envelop
virus
includ
hepatitisc
viru
human
cytomegaloviru
herp
simplex
viru
demonstr
repres
broadli
activ
antivir
compound
prospect
microbicid
drug
develop
lump
et
al
thu
evalu
whether
might
also
block
infect
reemerg
envelop
virus
show
inde
inhibit
infect
replicationcompet
ebov
zikv
well
marburg
rabi
sar
corona
viru
sarscov
pseudoparticl
lost
antivir
activ
presenc
serum
remain
activ
presenc
semen
urin
saliva
cerebrospin
fluid
thu
broadli
activ
compound
repres
promis
lead
develop
microbicid
protect
sexual
acquisit
zikv
ebov
topic
appli
drug
therapi
viral
infect
skin
mucosa
respiratori
tract
synthes
describ
previous
fokken
et
al
talbierski
et
al
mm
stock
solut
prepar
pb
zikv
envelop
protein
order
fitzgerald
industri
intern
acton
usa
vero
cell
use
propag
infect
zikv
describ
tcid
valu
tissu
cultur
infecti
dose
tcid
ml
determin
accord
reed
muench
multipli
factor
obtain
pfuml
plaqu
form
unit
normal
number
cell
use
calcul
respect
moi
multipl
infect
human
epitheli
colon
carcinoma
cell
kindli
provid
ninel
azoitei
center
intern
medicin
univers
ulm
ulm
germani
hff
human
foreskin
fibroblast
human
glioblastoma
neuroglioma
cell
kindli
provid
jen
von
einem
karin
danzer
ulm
univers
medic
center
ulm
germani
hepat
cell
kindli
provid
germani
report
cell
line
tzmbl
obtain
nih
arrrp
viru
stock
gener
transient
transfect
cell
describ
et
al
method
describ
effect
pseudotyp
lentivir
particl
ebola
viru
infect
detect
zikv
infect
colorimetr
mtt
assay
cellbas
zikv
immunodetect
assay
flow
cytometri
confoc
microscopi
well
rna
releas
assay
antivir
activ
bodi
fluid
found
supplement
shown
previous
inhibit
infect
disrupt
viral
membran
lump
et
al
suggest
antivir
activ
tweezer
independ
presenc
viral
glycoprotein
test
hypothesi
gener
luciferaseencod
retrovir
particl
harbor
glycoprotein
deriv
ebov
close
relat
filoviru
marburg
viru
rabi
viru
rhabdovirida
sarscov
coronavirida
pseudoparticl
expos
ad
cell
lack
hydrophob
side
arm
activ
lump
et
al
serv
neg
control
infect
rate
determin
three
day
later
quantifi
luciferas
activ
show
contrast
effici
block
infect
test
pseudoparticl
fig
halfmaxim
inhibitori
concentr
ic
four
pseudoparticl
similar
rang
rabi
marburg
viru
fig
data
corrobor
previou
find
target
viral
membran
rather
viral
glycoprotein
lump
et
al
test
next
whether
block
infect
replicationcompet
pathogen
ebov
vero
cell
inocul
gfpencod
ebov
ebihara
et
al
hoenen
et
al
expos
day
number
virusinduc
plaqu
reveal
reduc
infecti
titer
dosedepend
manner
ic
fig
next
determin
effect
zikv
infect
vero
cell
inocul
african
zikv
strain
isol
sentinel
rhesu
macaqu
dick
et
al
absenc
presenc
viral
replic
monitor
light
microscopi
absenc
zikv
caus
profound
cytopath
effect
cpe
evidenc
larg
plaqu
caus
detach
cell
effect
phenotyp
fig
howev
exposur
prevent
format
virusinduc
cpe
entir
quantit
assess
antivir
activ
use
colorimetr
mtt
assay
measur
viral
induc
cpe
et
al
absenc
compound
presenc
zikv
result
dead
detach
cell
contrast
suppress
cpe
format
ic
fig
mtt
assay
allow
indirect
measur
zikv
infect
tetrazolium
dye
metabol
live
noninfect
cell
evalu
effect
zikv
directli
infect
cell
stain
viral
e
protein
analyz
confoc
microscopi
schandock
et
al
upon
treatment
e
proteinspecif
fluoresc
could
detect
wherea
effect
expect
fig
lack
e
protein
express
cell
infect
viru
confirm
flow
cytometri
fig
supplementari
fig
note
cytotox
concentr
activ
zikv
supplementari
fig
caus
alter
cell
morpholog
compar
confoc
imag
dot
plot
uninfect
cell
vs
expos
cell
fig
thu
prevent
zikv
infect
vero
cell
hypothes
inhibit
zikv
infect
similar
mechan
envelop
virus
activ
would
direct
viral
membran
lump
et
al
inde
ad
cell
rather
viru
wash
prior
infect
antivir
effect
observ
cellbas
zikv
immunodetect
assay
fig
perform
next
timecours
analysi
zikv
expos
prior
infect
alreadi
exposur
reduc
infect
infect
declin
increas
incub
time
nearli
level
uninfect
cell
incub
fig
agreement
direct
activ
rhabdovirida
rabi
viru
coronavirida
famili
sarscov
expos
indic
concentr
use
infect
cell
three
day
infect
rate
determin
quantifi
firefli
luciferas
activ
subtract
background
activ
deriv
uninfect
cell
valu
repres
report
gene
activ
sd
deriv
triplic
infect
normal
valu
obtain
cell
infect
absenc
tweezer
b
analysi
replic
compet
ebov
perform
use
confluent
vero
cell
plate
rgebovegfp
preincub
mixtur
ad
cell
day
sampl
analyz
count
number
plaqu
per
well
calcul
correspond
plaqu
form
unit
per
millilit
pfuml
inhibitor
dilut
display
valu
repres
mean
three
independ
experi
sd
ic
valu
calcul
graphpad
prism
oneway
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
appli
compar
differ
concentr
cell
infect
absenc
compound
denot
p
denot
p
denot
p
light
microscopi
imag
vero
cell
infect
zikv
absenc
presenc
imag
taken
day
post
infect
dpi
b
zikv
incub
mixtur
use
infect
vero
cell
day
signific
cytopath
effect
visibl
number
adher
viabl
cell
determin
use
mtt
assay
et
al
valu
repres
mean
sd
percentag
deriv
triplic
infect
ic
determin
use
graphpad
prism
oneway
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
appli
compar
differ
concentr
cell
infect
absenc
compound
denot
p
c
confoc
microscopi
imag
vero
cell
infect
zikv
day
post
infect
cell
stain
zikv
e
protein
green
nuclei
hoechst
blue
imag
use
confoc
microscopi
scale
bar
flow
cytometri
infect
vero
cell
viru
pretreat
pb
ad
cell
h
later
cell
fix
permeabil
stain
anti
e
protein
antibodi
quantifi
use
alexa
secondari
antibodi
percentag
indic
fraction
protein
e
posit
cell
ic
isotyp
control
ae
et
al
antivir
research
virion
ic
increas
higher
multipl
infect
appli
supplementari
fig
shown
destroy
membran
integr
interact
raftrich
region
retrovir
envelop
lump
et
al
contrast
zikv
particl
rel
dens
pack
glycoprotein
sirohi
et
al
might
hamper
interact
tweezer
zikv
membran
determin
whether
might
inhibit
zikv
infect
direct
interact
glycoprotein
increas
amount
recombin
viral
e
protein
titrat
solut
assay
antizikv
activ
shown
fig
even
eantigen
concentr
affect
antivir
activ
suggest
tweezer
reduc
zikv
infect
bind
viral
e
protein
interestingli
also
observ
elev
eantigen
concentr
reduc
infect
absenc
fig
like
due
competit
virionassoci
e
protein
recombin
e
protein
cellular
receptor
test
whether
interact
viral
particl
result
loss
membran
integr
shown
case
lump
et
al
measur
viral
rna
genom
releas
sucros
cushion
purifi
zikv
incub
pb
triton
posit
control
min
amount
total
rna
solut
determin
fluorometr
expect
viral
viru
treatment
zikv
incub
min
room
temperatur
mixtur
ad
vero
cell
cell
treatment
ad
directli
cell
h
medium
replac
cell
infect
zikv
dpi
cellbas
zikv
immunodetect
assay
perform
valu
repres
mean
sd
n
oneway
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
appli
compar
differ
concentr
cell
infect
absenc
compound
denot
p
denot
p
b
zikv
incub
indic
time
pb
mixtur
ad
vero
cell
dpi
cellbas
zikv
immunodetect
assay
perform
valu
repres
mean
sd
n
oneway
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
appli
compar
cell
infect
zikv
cell
infect
zikv
incub
pb
time
period
denot
p
c
indic
concentr
zikv
e
protein
titrat
pb
zikv
ad
mixtur
use
inocul
vero
cell
dpi
number
adher
viabl
cell
determin
use
mtt
assay
et
al
valu
shown
mean
sd
triplic
infect
oneway
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
appli
compar
cell
treat
differ
concentr
zikv
e
protein
cell
treat
concentr
e
protein
pb
denot
p
zikv
incub
pb
triton
min
sampl
inactiv
uv
light
laminar
flow
min
sampl
use
determin
rna
concentr
use
quantifluor
rna
system
quantu
fluoromet
promega
background
valu
obtain
control
sampl
use
cell
supernat
uninfect
cell
subtract
respect
signal
rna
level
viru
stock
incub
pb
subtract
valu
data
point
repres
mean
sd
n
oneway
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
appli
compar
sampl
treat
differ
concentr
triton
pbstreat
viru
denot
p
ae
et
al
antivir
research
rna
detect
zikv
incub
buffer
fig
contrast
incub
triton
result
readili
detect
viral
rna
suggest
deterg
lyse
zikv
particl
similarli
elev
amount
rna
detect
upon
treatment
zikv
demonstr
physic
destruct
viral
particl
tweezer
note
act
deterg
target
viral
membran
lump
et
al
next
analyz
whether
activ
epidem
zikv
strain
isol
deriv
fetu
pregnant
finnish
tourist
return
south
america
drigger
et
al
isol
repres
current
american
epidem
strain
isol
puerto
rican
patient
lanciotti
et
al
zikv
strain
expos
upon
infect
vero
cell
cellbas
immunodetect
assay
flow
cytometri
experi
demonstr
tweezer
suppress
infect
strain
ic
valu
fig
supplementari
fig
fig
respect
zikv
transmit
via
sexual
intercours
studi
whether
zikv
infect
cell
deriv
anogenit
region
whether
infect
block
zikv
effect
infect
cell
line
deriv
cervix
fig
supplementari
fig
colon
fig
supplementari
fig
primari
foreskin
cell
fig
supplementari
fig
viral
infect
suppress
ic
valu
rang
fig
supplementari
fig
zikv
neurotrop
caolormeau
et
al
mlakar
et
al
shown
previous
penetr
bloodbrain
barrier
bbb
administ
system
richter
et
al
also
test
whether
block
zikv
infect
brainderiv
cell
glioblastoma
neuroglioma
cell
suscept
zikv
infect
entir
abrog
infect
fig
final
confirm
find
obtain
human
cell
line
use
primari
murin
cerebellar
neuron
zikv
infect
neuron
bystand
cell
block
fig
appar
toxic
primari
neuron
concentr
antivir
effect
abrog
serum
urin
saliva
semen
csf
broad
antivir
activ
make
interest
lead
compound
antivir
prevent
treatment
system
applic
must
retain
antivir
activ
blood
test
whether
case
dilut
human
serum
expos
zikv
shown
fig
serum
concentr
higher
abrog
antizikv
activ
tweezer
similarli
serum
also
abrog
activ
supplementari
fig
preclud
use
system
appli
antivir
drug
contrast
remain
activ
inhibit
zikv
infect
presenc
urin
fig
saliva
fig
cerebrospin
fluid
fig
human
semen
fig
thu
inactiv
zikv
presenc
bodi
fluid
associ
viru
transmiss
could
administ
local
halt
viru
replic
appli
topic
microbicid
prevent
eg
sexual
viru
transmiss
thereaft
vero
cell
infect
day
later
infect
rate
determin
via
cellbas
zikv
immunodetect
assay
data
point
repres
mean
sd
n
ic
valu
determin
graphpad
prism
oneway
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
appli
compar
differ
concentr
cell
infect
absenc
compound
denot
p
denot
p
zikv
incub
min
next
mixtur
use
inocul
hela
b
hff
c
cell
day
later
infect
rate
determin
via
quantif
viral
e
protein
use
cellbas
zikv
immunodetect
assay
data
point
repres
mean
sem
n
oneway
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
appli
compar
differ
concentr
cell
infect
absenc
compound
denot
p
denot
p
denot
p
ae
et
al
antivir
research
discuss
result
establish
broadspectrum
antivir
agent
inhibit
infect
establish
viral
pathogen
lump
et
al
also
emerg
virus
ebov
zikv
character
mainli
effect
zikv
current
specif
antivir
therapi
prevent
vaccin
avail
block
zikv
infect
primari
brainderiv
murin
cell
fig
well
human
cell
line
deriv
anogenit
region
fig
supplementari
fig
brain
fig
ic
valu
valu
rang
ic
valu
obtain
ebov
fig
lump
et
al
sever
line
evid
demonstr
antivir
activ
direct
zikv
particl
first
treatment
cell
prior
infect
antivir
effect
fig
second
ic
increas
increas
viral
concentr
supplementari
fig
third
integr
zikv
particl
lost
upon
treatment
shown
releas
viral
rna
virion
fig
find
agreement
previou
observ
select
disrupt
viral
membran
lump
et
al
interestingli
select
stem
preferenti
interact
membran
contain
high
level
sphingomyelin
cholesterol
two
lipid
enrich
membran
envelop
virus
ebov
bavari
et
al
et
al
chazal
gerlier
loriz
et
al
select
interact
lipid
enrich
viral
cellular
membran
may
also
explain
minim
effect
cell
viabil
ferreira
et
al
lope
et
al
prabhudesai
et
al
sinha
et
al
fig
supplementari
fig
slightli
cytotox
concentr
mm
correspond
select
indic
reason
rang
drug
develop
buschmann
mannhold
food
drug
administr
inhibit
infect
human
murin
brain
cell
human
glioblastoma
neuroglioma
cell
infect
zikv
presenc
absenc
two
day
later
cell
stain
zikv
e
protein
green
nuclei
hoechst
blue
imag
confoc
microscopi
scale
bar
b
primari
murin
cerebellum
cultur
infect
zikv
incub
min
dpi
cultur
fix
permeabil
stain
neuron
protein
tubulin
red
zikv
e
protein
green
nuclei
hoechst
blue
scale
bar
lost
antivir
activ
presenc
serum
preclud
applic
system
antivir
drug
find
unexpect
found
previous
stabl
mous
human
plasma
halflif
h
mice
sc
iv
inject
moreov
show
therapeut
effect
anim
model
alzheim
parkinson
diseas
malik
et
al
prabhudesai
et
al
richter
et
al
data
suggest
loss
antivir
activ
presenc
serum
like
due
bind
serum
protein
concentr
requir
prevent
amyloid
format
vitro
vivo
submicromolar
rang
order
magnitud
lower
need
block
viral
infect
presum
vast
major
bound
serum
protein
henc
unavail
act
viru
wherea
minor
tweezer
remain
free
concentr
allow
exert
antiamyloid
activ
interpret
also
support
observ
retain
antizikv
activ
semen
urin
saliva
csf
total
protein
concentr
bodi
fluid
order
magnitud
lower
serum
hu
et
al
vibhakar
et
al
thu
larger
percentag
molecul
like
free
biofluid
henc
antivir
activ
describ
previous
novel
bifunct
microbicid
counteract
sexual
transmiss
directli
target
viru
infect
inhibit
infectionpromot
activ
amyloid
semen
lump
et
al
show
tweezer
also
inhibit
pathogen
zikv
infect
cell
deriv
anogenit
region
presenc
semen
interestingli
zikv
ebov
present
semen
infect
individu
atkinson
et
al
deen
et
al
moreira
et
al
transmit
sexual
intercours
similar
dortenzio
et
al
mate
et
al
moreira
et
al
thu
applic
microbicid
vagin
rectal
tract
might
protect
acquir
differ
viral
pathogen
interestingli
shown
penetr
bbb
richter
et
al
may
also
block
replic
neurotrop
virus
zika
rabi
caolormeau
et
al
ludlow
et
al
mlakar
et
al
howev
need
consid
may
block
cellfre
viru
infect
celltocel
viral
spread
may
limit
util
therapeut
agent
therefor
effect
celltocel
viral
transmiss
need
explor
anoth
mean
applic
topic
eg
directli
administ
virusinfect
bodi
surfac
skin
mucou
membran
treat
eg
hsvinduc
herp
labiali
genitali
topic
medic
may
also
inhal
medic
flu
respiratori
syncyti
viru
rsv
appli
surfac
tissu
min
incub
mixtur
use
infect
vero
cell
day
later
infect
rate
determin
via
cellbas
zikv
immunodetect
assay
data
point
repres
mean
sem
n
except
csf
serum
mean
sd
n
oneway
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
appli
compar
differ
concentr
cell
infect
absenc
presenc
respect
bodi
fluid
concentr
denot
p
denot
p
ae
et
al
antivir
research
skin
eye
drop
appli
conjunctiva
exampl
cmvinduc
retin
address
challeng
emerg
reemerg
viral
pathogen
imper
develop
broadspectrum
class
antivir
agent
convent
onebugonedrug
paradigm
insuffici
zhu
et
al
current
directact
antivir
drug
highli
success
narrow
spectrum
coverag
avail
limit
number
viral
pathogen
moreov
drug
develop
slow
expens
typic
take
decad
get
market
approv
current
specif
antivir
treatment
exist
emerg
reemerg
virus
broadspectrum
antivir
may
offer
certain
advantag
reduc
time
cost
drug
develop
allow
offlabel
use
could
appli
even
viral
threat
diagnos
bekerman
einav
zhu
et
al
broadli
activ
envelop
virus
disrupt
lipid
bilay
contain
elev
level
sphingomyelin
cholesterol
lump
et
al
typic
enrich
viral
membran
bavari
et
al
et
al
chan
et
al
chazal
gerlier
loriz
et
al
shown
inactiv
major
viral
pathogen
cmv
hcv
well
zikv
ebov
highli
like
also
block
envelop
virus
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
corona
virus
influenza
rsv
notabl
resist
develop
unlik
occur
would
requir
chang
lipid
composit
cellular
viral
membran
difficult
envisag
conclus
repres
promis
prototyp
broadspectrum
antivir
agent
data
analyz
use
graphpad
prism
version
window
graphpad
softwar
la
jolla
california
usa
wwwgraphpad
com
signific
level
calcul
use
oneway
oneway
analysi
varianc
anova
nonparametr
group
follow
bonferroni
multipl
comparison
test
p
valu
consid
signific
p
p
p
